ResMed (NYSE:RMD) Director Sells $1,800,000.00 in Stock

ResMed Inc. (NYSE:RMD) Director Peter Farrell sold 8,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $225.00, for a total value of $1,800,000.00. Following the transaction, the director owned 52,773 shares of the company’s stock, valued at approximately $11,873,925. This represents a 13.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ResMed Stock Performance

Shares of RMD stock opened at $211.84 on Friday. The firm has a market capitalization of $30.73 billion, a price-to-earnings ratio of 20.31, a PEG ratio of 1.29 and a beta of 0.76. The stock has a fifty day moving average of $200.49 and a 200 day moving average of $222.23. ResMed Inc. has a 52 week low of $180.26 and a 52 week high of $293.81. The company has a quick ratio of 2.33, a current ratio of 3.01 and a debt-to-equity ratio of 0.06.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $2.95 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.89 by $0.06. ResMed had a net margin of 26.94% and a return on equity of 25.86%. The business had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.46 billion. During the same period in the previous year, the firm earned $2.55 EPS. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. As a group, research analysts expect that ResMed Inc. will post 12 earnings per share for the current year.

ResMed Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 24th. Investors of record on Thursday, August 20th will be given a dividend of $0.66 per share. This is an increase from ResMed’s previous quarterly dividend of $0.60. This represents a $2.64 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Thursday, August 20th. ResMed’s dividend payout ratio is presently 23.14%.

Hedge Funds Weigh In On ResMed

A number of institutional investors and hedge funds have recently made changes to their positions in RMD. Terra Nova Asset Management LLC grew its stake in shares of ResMed by 0.6% in the 3rd quarter. Terra Nova Asset Management LLC now owns 7,805 shares of the medical equipment provider’s stock worth $2,136,000 after buying an additional 46 shares during the last quarter. Kera Capital Partners Inc. boosted its holdings in ResMed by 6.6% in the fourth quarter. Kera Capital Partners Inc. now owns 841 shares of the medical equipment provider’s stock worth $217,000 after acquiring an additional 52 shares in the last quarter. Andina Capital Management LLC boosted its holdings in ResMed by 2.9% in the fourth quarter. Andina Capital Management LLC now owns 1,988 shares of the medical equipment provider’s stock worth $479,000 after acquiring an additional 56 shares in the last quarter. Turtle Creek Wealth Advisors LLC grew its stake in shares of ResMed by 6.2% in the first quarter. Turtle Creek Wealth Advisors LLC now owns 994 shares of the medical equipment provider’s stock worth $223,000 after acquiring an additional 58 shares during the last quarter. Finally, Stratos Wealth Partners LTD. grew its stake in shares of ResMed by 4.6% in the fourth quarter. Stratos Wealth Partners LTD. now owns 1,355 shares of the medical equipment provider’s stock worth $326,000 after acquiring an additional 59 shares during the last quarter. Institutional investors own 54.98% of the company’s stock.

Key Stories Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: ResMed reported fiscal Q4 earnings of $2.95 per share, beating the approximately $2.89–$2.90 consensus and rising from $2.55 a year earlier. Revenue increased 8.6% year over year to $1.46 billion, in line with estimates. ResMed Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: The company raised its quarterly dividend from $0.60 to $0.66 per share, a 10% increase. The dividend is payable September 24 to shareholders of record on August 20, supporting ResMed’s income-investment appeal. ResMed Posts Strong Q4 Earnings and Lifts Dividend
• Positive Sentiment: Royal Bank of Canada raised its price target to $244 from $234 while retaining a “sector perform” rating, indicating potential upside from recent trading levels. Benzinga analyst action
• Neutral Sentiment: Analyst sentiment remains mixed. Piper Sandler lowered its target to $225 and Wells Fargo cut its target to $215; both maintain neutral or equal-weight ratings. The overall analyst consensus remains “Hold,” despite a consensus target near $246. ResMed Analyst Ratings
• Negative Sentiment: The primary pressure on RMD is forward guidance: fiscal 2027 revenue expectations reportedly trail consensus, raising concerns that growth may moderate even after the quarterly earnings beat. RMD Stock Down Despite Q4 Earnings Beat
• Negative Sentiment: Director Peter Farrell sold 8,000 shares worth $1.8 million. The sale was made under a pre-arranged Rule 10b5-1 plan, reducing its negative signaling value, but it may add modest short-term selling pressure. SEC Insider Trading Filing

Wall Street Analyst Weigh In

RMD has been the subject of several research analyst reports. Royal Bank Of Canada raised their price objective on shares of ResMed from $234.00 to $244.00 and gave the stock a “sector perform” rating in a report on Friday. Jefferies Financial Group reduced their target price on ResMed from $240.00 to $225.00 and set a “hold” rating on the stock in a report on Friday, July 10th. Weiss Ratings lowered ResMed from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, July 24th. Piper Sandler lowered their target price on ResMed from $233.00 to $225.00 and set a “neutral” rating for the company in a research note on Friday. Finally, UBS Group restated a “buy” rating and set a $300.00 price target on shares of ResMed in a research report on Tuesday, July 21st. Seven research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $240.17.

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.